
Spectris Misses Primary End Point in Pivotal HOPE Trial for Alzheimer Disease
Key Takeaways
- A 12-month, multicenter, randomized, double-blind, sham-controlled trial in biomarker-confirmed Alzheimer disease found no significant separation from sham on primary or secondary outcomes in the mITT population.
- Prespecified mild Alzheimer disease subgroup analyses showed nominal slowing on ADCS-ADL, instrumental ADL, and CDR-SB, while iADMARS and MMSE did not reach nominal significance.
In the prespecified mild subgroup of HOPE, 40-Hz gamma sensory stimulation was associated with 56% slowing on the ADCS-ADL and 47% slowing on the CDR-SB vs sham at 12 months.
Newly presented data revealed that Cognito Therapeutics’ Spectris, an investigational at-home device delivering 40-Hz light and sound stimulation, did not meet its primary end point in the pivotal HOPE study (NCT05637801) among patients with mild-to-moderate
Despite missing the primary end point, findings from a prespecified subgroup of patients with mild disease showed that the device nominally slowed decline on measures of daily function and disease severity compared with sham. Senior author
“While the HOPE study did not meet its primary endpoint, the signal in the mild Alzheimer’s subgroup raises important questions that are worth exploring further,”
HOPE Study Design
HOPE was a 12-month, multicenter, randomized, double-blind, sham-controlled study that enrolled 673 participants with biomarker-confirmed AD and baseline Mini-Mental State Examination (MMSE) scores of 15 to 28. Participants used the device for 1 hour daily and were stratified into mild (MMSE 21-28) and moderate (MMSE 15-20) subgroups. The primary end point was change at month 12 on iADMARS, an equally weighted composite of the MMSE and the Alzheimer’s Disease Cooperative Study–Activities of Daily Living (ADCS-ADL) scale. In the overall modified intention-to-treat (mITT) population (n = 663), neither the primary nor secondary end points differed significantly from sham.1
Efficacy in the Mild AD Subgroup
In the mild subgroup (n = 395), Spectris was associated with 56% slowing on the ADCS-ADL relative to sham at month 12 (difference, 2.03; P = .016), 53% slowing on the ADCS-instrumental ADL (P = .034), and 47% slowing on the Clinical Dementia Rating–Sum of Boxes (CDR-SB; difference, −0.58; P = .004). The iADMARS composite (42%; P = .072) and the MMSE (29%; P = .369) did not reach nominal significance. Exploratory estimates suggested 5.3 to 5.6 months of time saved.1,2
READ MORE:
A prespecified per-protocol analysis of patients with mild AD (n = 169) with at least 6 months of treatment and 70% or greater compliance showed 82% slowing on the ADCS-ADL (P = .002), 64% on the CDR-SB (P = .005), and 73% on the iADMARS (P = .017). Cognito noted that per-protocol analyses are subject to adherence-related bias and do not establish causation.1
Safety Findings
No unanticipated adverse device effects were reported. Adverse device effects occurred in 18.3% of active-treatment participants (n = 333) vs 15.5% of sham participants (n = 330), most commonly headache (5.7% vs 3.9%) and tinnitus (3.3% vs 1.2%). Seizure, an adverse event of special interest, occurred in 0.9% vs 0.3%. Unlike antiamyloid therapies, Spectris is not expected to cause amyloid-related imaging abnormalities (ARIA).1
Gamma Sensory Stimulation and Prior Data
Spectris is designed to evoke 40-Hz gamma oscillations through synchronized visual and auditory stimulation, an approach that has shown promising disease-modifying effects in experimental AD models.4 In the 6-month phase 2 OVERTURE trial (NCT03556280; n = 76), the device was well tolerated with no ARIA; it did not separate from sham on its primary clinical outcome or CDR-SB, although ADCS-ADL, MMSE, and whole-brain volume showed nominally reduced progression.4
Limitations and Next Steps
The findings warrant caution since the trial missed its primary end point, and subgroup results are nominal and unadjusted for multiplicity. Spectris AD holds FDA breakthrough device designation but is not authorized. Cognito plans to engage the FDA to review the HOPE results and discuss a De Novo submission for early symptomatic AD; an open-label extension study (NCT06245031) is ongoing.1
REFERENCES
1. Cognito’s non-invasive, at-home therapy Spectris showed consistent slowing of cognitive and functional decline in early symptomatic Alzheimer’s disease in HOPE pivotal study. News release. Cognito Therapeutics. November 16, 2026. Accessed November 17, 2026. https://www.businesswire.com/news/home/20261116639625/en/
2. Hamilton R, Kern R, Zusterzeel R, Sabbagh M. Spectris treatment in mild-to-moderate Alzheimer’s disease: topline results and secondary analyses from the HOPE pivotal study. Presented at: 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference; November 16-19, 2026; Boston, MA. Abstract LB01.
3. Cognito reports pivotal phase 3 results for Spectris AD, a non-invasive, at-home approach for Alzheimer’s treatment, backed by ADDF investment. News release. Alzheimer’s Drug Discovery Foundation. November 16, 2026. Accessed November 17, 2026. https://www.prnewswire.com/news-releases/cognito-reports-pivotal-phase-3-results-for-spectris-ad-a-non-invasive-at-home-approach-for-alzheimers-treatment-backed-by-addf-investment-302941264.html
4. Hajós M, Boasso A, Hempel E, et al. Safety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer's disease. Front Neurol. 2024;15:1343588. Published 2024 Mar 6. doi:10.3389/fneur.2024.1343588
Related to this article








